vs

Side-by-side financial comparison of Ultragenyx Pharmaceutical Inc. (RARE) and Regency Centers (REG). Click either name above to swap in a different company.

Regency Centers is the larger business by last-quarter revenue ($404.2M vs $207.3M, roughly 1.9× Ultragenyx Pharmaceutical Inc.). Regency Centers runs the higher net margin — 50.1% vs -62.0%, a 112.1% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 8.5%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 5.4%).

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Regency Centers Corporation is a real estate investment trust based in Jacksonville, Florida, and is one of the largest operators of shopping centers with grocery stores as anchor tenants. As of October 21, 2020, the company owned 415 properties comprising 56-million-square feet of space. Notable properties owned by the company include Serramonte Center and a 30% interest in Village District.

RARE vs REG — Head-to-Head

Bigger by revenue
REG
REG
1.9× larger
REG
$404.2M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+17.4% gap
RARE
25.9%
8.5%
REG
Higher net margin
REG
REG
112.1% more per $
REG
50.1%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
5.4%
REG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RARE
RARE
REG
REG
Revenue
$207.3M
$404.2M
Net Profit
$-128.6M
$202.5M
Gross Margin
Operating Margin
-54.7%
71.0%
Net Margin
-62.0%
50.1%
Revenue YoY
25.9%
8.5%
Net Profit YoY
3.5%
134.1%
EPS (diluted)
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RARE
RARE
REG
REG
Q4 25
$207.3M
$404.2M
Q3 25
$159.9M
$387.6M
Q2 25
$166.5M
$380.8M
Q1 25
$139.3M
$380.9M
Q4 24
$164.6M
$372.5M
Q3 24
$139.5M
$360.3M
Q2 24
$147.0M
$357.3M
Q1 24
$108.8M
$363.9M
Net Profit
RARE
RARE
REG
REG
Q4 25
$-128.6M
$202.5M
Q3 25
$-180.4M
$109.4M
Q2 25
$-115.0M
$106.0M
Q1 25
$-151.1M
$109.6M
Q4 24
$-133.2M
$86.5M
Q3 24
$-133.5M
$101.5M
Q2 24
$-131.6M
$102.7M
Q1 24
$-170.7M
$109.8M
Operating Margin
RARE
RARE
REG
REG
Q4 25
-54.7%
71.0%
Q3 25
-106.9%
72.7%
Q2 25
-64.8%
73.8%
Q1 25
-102.6%
71.8%
Q4 24
-74.3%
71.1%
Q3 24
-94.6%
72.5%
Q2 24
-79.1%
72.3%
Q1 24
-151.9%
72.3%
Net Margin
RARE
RARE
REG
REG
Q4 25
-62.0%
50.1%
Q3 25
-112.8%
28.2%
Q2 25
-69.0%
27.8%
Q1 25
-108.5%
28.8%
Q4 24
-80.9%
23.2%
Q3 24
-95.7%
28.2%
Q2 24
-89.5%
28.7%
Q1 24
-156.8%
30.2%
EPS (diluted)
RARE
RARE
REG
REG
Q4 25
$-1.28
Q3 25
$-1.81
Q2 25
$-1.17
Q1 25
$-1.57
Q4 24
$-1.34
Q3 24
$-1.40
Q2 24
$-1.52
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RARE
RARE
REG
REG
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
$4.7B
Stockholders' EquityBook value
$-80.0M
$6.9B
Total Assets
$1.5B
$13.0B
Debt / EquityLower = less leverage
0.69×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RARE
RARE
REG
REG
Q4 25
$421.0M
Q3 25
$202.5M
Q2 25
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$150.6M
Q2 24
$480.7M
Q1 24
$112.3M
Total Debt
RARE
RARE
REG
REG
Q4 25
$4.7B
Q3 25
$4.9B
Q2 25
$4.8B
Q1 25
$4.6B
Q4 24
$4.4B
Q3 24
$4.4B
Q2 24
$4.4B
Q1 24
$4.4B
Stockholders' Equity
RARE
RARE
REG
REG
Q4 25
$-80.0M
$6.9B
Q3 25
$9.2M
$6.8B
Q2 25
$151.3M
$6.7B
Q1 25
$144.2M
$6.7B
Q4 24
$255.0M
$6.7B
Q3 24
$346.8M
$6.8B
Q2 24
$432.4M
$6.8B
Q1 24
$140.3M
$7.0B
Total Assets
RARE
RARE
REG
REG
Q4 25
$1.5B
$13.0B
Q3 25
$1.2B
$13.1B
Q2 25
$1.3B
$12.7B
Q1 25
$1.3B
$12.6B
Q4 24
$1.5B
$12.4B
Q3 24
$1.5B
$12.4B
Q2 24
$1.6B
$12.4B
Q1 24
$1.3B
$12.7B
Debt / Equity
RARE
RARE
REG
REG
Q4 25
0.69×
Q3 25
0.72×
Q2 25
0.72×
Q1 25
0.69×
Q4 24
0.66×
Q3 24
0.65×
Q2 24
0.64×
Q1 24
0.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RARE
RARE
REG
REG
Operating Cash FlowLast quarter
$-99.8M
$203.9M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
1.01×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RARE
RARE
REG
REG
Q4 25
$-99.8M
$203.9M
Q3 25
$-91.4M
$218.7M
Q2 25
$-108.3M
$244.0M
Q1 25
$-166.5M
$161.0M
Q4 24
$-79.3M
$191.4M
Q3 24
$-67.0M
$227.6M
Q2 24
$-77.0M
$203.5M
Q1 24
$-190.7M
$167.8M
Free Cash Flow
RARE
RARE
REG
REG
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
RARE
RARE
REG
REG
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
RARE
RARE
REG
REG
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
RARE
RARE
REG
REG
Q4 25
1.01×
Q3 25
2.00×
Q2 25
2.30×
Q1 25
1.47×
Q4 24
2.21×
Q3 24
2.24×
Q2 24
1.98×
Q1 24
1.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

REG
REG

Shopping Centers$418.0M103%
Propertymanagementservices$4.1M1%
Assetmanagementservices$1.7M0%

Related Comparisons